| Malignant neoplasm of breast

Halaven vs Kisqali

Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.

Deep comparison between: Halaven vs Kisqali with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKisqali has a higher rate of injection site reactions vs Halaven based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Kisqali but not Halaven, including UnitedHealthcare

Category

Halaven

Kisqali

At A Glance

RouteIV infusion

FrequencyDays 1 and 8 of a 21-day cycle

ClassMicrotubule dynamics inhibitor

RouteOral

FrequencyOnce daily (21/28-day cycle)

ClassCDK4/6 inhibitor

Indications

Malignant neoplasm of breast
Sarcoma

Malignant neoplasm of breast
Advanced breast cancer

Dosing

Malignant neoplasm of breast, Sarcoma 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle; reduce to 1.1 mg/m2 for mild hepatic impairment (Child-Pugh A) or moderate/severe renal impairment (CLcr 15-49 mL/min); reduce to 0.7 mg/m2 for moderate hepatic impairment (Child-Pugh B).

Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.

Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.

Contraindications

—

Drug Interactions

1087View drug interactions

1170View drug interactions

Adverse Reactions

Most common (>=25%) - Metastatic breast cancer Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation

Most common (>=25%) - Liposarcoma and leiomyosarcoma Fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, pyrexia

Serious Febrile neutropenia, neutropenia

Postmarketing Lymphopenia, pancreatitis, hepatotoxicity, drug hypersensitivity, pneumonia, sepsis/neutropenic sepsis, interstitial lung disease, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis

Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain

Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia

Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS

Pharmacology

Eribulin mesylate is a microtubule dynamics inhibitor that inhibits the growth phase of microtubules, sequesters tubulin into nonproductive aggregates, and exerts antimitotic effects via G2/M cell-cycle block and disruption of mitotic spindles, ultimately leading to apoptotic cell death after prolonged mitotic blockage.

Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Halaven